Research map: Six-month outcomes with a reduced two-injection induction (2+TAE) regimen of aflibercept 8 mg in treatment-naive neovascular age-related macular degeneration

Back to the article

Papers in this map

  1. Ranibizumab for Neovascular Age-Related Macular Degeneration · Philip J. Rosenfeld · 2006 · 5929 citations · Cited by this paper
  2. Corrected gestational age–specific prediction models for identifying treatment-requiring retinopathy of prematurity · 2026 · Related
  3. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration · Jeffrey S. Heier · 2012 · 2521 citations · Cited by this paper
  4. Ultra-widefield indocyanine green angiography findings of vortex veins in central serous chorioretinopathy · 2026 · Related
  5. Clinical Classification of Age-related Macular Degeneration · Frederick L. Ferris · 2013 · 1891 citations · Cited by this paper
  6. Endoluminal lacrimal duct recanalization for pediatric lacrimal duct obstruction: etiologic spectrum and surgical outcomes · 2026 · Related
  7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration · Pravin U. Dugel · 2019 · 938 citations · Cited by this paper
  8. Clinical performance of the multiplex solid-phase “Direct Strip PCR” for infectious uveitis: a multicenter diagnostic accuracy study · 2026 · Related
  9. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data · Richard F. Spaide · 2019 · 831 citations · Cited by this paper
  10. Establishing absolute and vitreous-normalized reference apparent diffusion coefficient values of the lacrimal gland in healthy individuals · 2026 · Related
  11. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials · Jeffrey S Heier · 2022 · 788 citations · Cited by this paper
  12. Clinical characteristics of angioid streaks in Japanese patients · 2026 · Related
  13. Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration · Maureen G. Maguire · 2016 · 709 citations · Cited by this paper
  14. Optic nerve head abnormalities in primary open-angle glaucoma and their associations with axial length · 2026 · Related
  15. INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY · Richard F. Spaide · 1995 · 613 citations · Cited by this paper
  16. Collaborative care for retinal artery occlusion by ophthalmologists and vascular neurologists: management of systemic complications · 2026 · Related
  17. Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese Patients · Ichiro Maruko · 2007 · 547 citations · Cited by this paper
  18. Trends in childhood myopia over a 5-year interval: Korea national health and nutrition examination survey 2016 and 2021 · 2026 · Related
  19. Polypoidal Choroidal Vasculopathy · Chui Ming Gemmy Cheung · 2020 · 525 citations · Cited by this paper
  20. Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma · 2026 · Related
  21. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study · Won Ki Lee · 2018 · 275 citations · Cited by this paper
  22. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial · Paolo Lanzetta · 2024 · 262 citations · Cited by this paper
  23. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR · Masahito Ohji · 2020 · 259 citations · Cited by this paper
  24. Nine-Year Incidence and Risk Factors for Age-Related Macular Degeneration in a Defined Japanese PopulationThe Hisayama Study · Miho Yasuda · 2009 · 155 citations · Cited by this paper
  25. Prevalence and Risk Factors for Age-Related Macular Degeneration in an Adult Japanese Population · Ryo Kawasaki · 2008 · 139 citations · Cited by this paper
  26. Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration · Charles C. Wykoff · 2017 · 130 citations · Cited by this paper
  27. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis · D Rosenberg · 2022 · 89 citations · Cited by this paper
  28. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration · Ichiro Maruko · 2020 · 50 citations · Cited by this paper
  29. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration · Hidetaka Matsumoto · 2024 · 36 citations · Cited by this paper
  30. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan · Ryo Mukai · 2024 · 32 citations · Cited by this paper
  31. Non-ICGA treatment criteria for Suboptimal Anti-VEGF Response for Polypoidal Choroidal Vasculopathy: APOIS PCV Workgroup Report 2 · Kelvin Yi Chong Teo · 2021 · 30 citations · Cited by this paper
  32. Association of ARMS2 Genotype With Bilateral Involvement of Exudative Age-Related Macular Degeneration · Hiroshi Tamura · 2012 · 27 citations · Cited by this paper
  33. Japanese clinical guidelines for neovascular age-related macular degeneration · Tomohiro Iida · 2025 · 24 citations · Cited by this paper
  34. Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report · Nozomu Hashiya · 2025 · 13 citations · Cited by this paper
  35. Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan · Yasuo Yanagi · 2024 · 8 citations · Cited by this paper
  36. Blood flow pattern in eye before development of type 3 macular neovascularization · Saya Yamaguchi · 2023 · 2 citations · Cited by this paper
  37. Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration · Keiko Kataoka · 2025 · 2 citations · Cited by this paper
  38. Untitled · Cited by this paper

Source: OpenAlex (CC0)